CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum Feb 20, 2025 09:00AM
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference Feb 19, 2025 09:00AM
CNS Pharmaceuticals (CNSP) announces 1-for-50 reverse stock split Feb 19, 2025 08:36AM
CNS Pharmaceuticals Announces Reverse Stock Split Feb 19, 2025 08:30AM
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit Feb 18, 2025 09:00AM
View Older Stories

Jul 3, 2024 11:16AM CNS Pharmaceuticals (CNSP) Prices 1.425M Share Offering at $1.39/sh
Jul 3, 2024 11:10AM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 26, 2024 08:03AM CNS Pharmaceuticals (CNSP) Prices Share and Warrant Offering at $2.45/sh
Jun 26, 2024 08:00AM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 14, 2024 03:13PM CNS Pharmaceuticals (CNSP) Prices Registered Direct Offering and Concurrent Private Placement
Jun 14, 2024 03:11PM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 3, 2024 08:08AM CNS Pharmaceuticals (CNSP) Announces 1-for-50 Reverse Stock Split
Jun 3, 2024 08:05AM CNS Pharmaceuticals Announces Reverse Stock Split
Jun 3, 2024 08:05AM CNS Pharmaceuticals Announces Reverse Stock Split
Apr 23, 2024 09:00AM CNS Pharmaceuticals to Present at the LSX World Congress 2024
Apr 22, 2024 12:00AM CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
Apr 1, 2024 04:26PM CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Apr 1, 2024 09:05AM CNS Pharmaceuticals to Present at Two Investor Conferences in April
Jan 30, 2024 05:48AM CNS Pharmaceuticals (CNSP) Prices 13.33M Share Offering at $0.30/sh
Jan 29, 2024 09:00PM CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Jan 18, 2024 08:46AM CNS Pharmaceuticals (CNSP) Appoints Amy Mahery to its Board
Jan 18, 2024 08:45AM Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Jan 17, 2024 08:45AM CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Dec 18, 2023 08:40AM CNS Pharmaceuticals (CNSP) Announces Successful Interim Analysis of Efficacy and Safety Data in Study of Berubicin
Dec 18, 2023 08:35AM CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
Nov 22, 2023 09:08AM CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Nov 22, 2023 09:05AM CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Nov 15, 2023 08:00AM CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Oct 19, 2023 09:05AM CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Oct 11, 2023 08:45AM CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Da
Sep 7, 2023 08:45AM CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Sep 5, 2023 08:45AM CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 08:39AM CNS Pharmaceuticals (CNSP) Presents Updated Results from On-Going Study of Berubicin
Aug 14, 2023 08:35AM CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Lin
Aug 14, 2023 07:35AM CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Aug 3, 2023 08:15AM CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Aug 3, 2023 08:04AM CNS Pharmaceuticals (CNSP) Provides Clinical Trial Update for Ongoing Study with Berubicin
Aug 3, 2023 08:00AM CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Jul 27, 2023 09:05AM CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
Jul 5, 2023 08:45AM CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series
Jun 14, 2023 09:05AM CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
May 15, 2023 08:35AM CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 08:48AM CNS Pharmaceuticals (CNSP) Appoints Bettina M. Cockroft to its Board
May 8, 2023 08:45AM Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
May 3, 2023 08:47AM CNS Pharmaceuticals (CNSP) Retains Shareholder Intelligence Services to Investigate Potential Naked Short Selling
May 3, 2023 08:45AM CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
Apr 27, 2023 08:45AM CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
Apr 10, 2023 08:45AM Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 6, 2023 09:05AM CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Apr 3, 2023 08:05AM CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 29, 2023 09:05AM CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
Mar 13, 2023 07:05AM CNS Pharmaceuticals (CNSP) Has No Exposure to Silicon Valley Bank Issues
Mar 13, 2023 07:05AM CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues
Mar 9, 2023 09:05AM CNS Pharmaceuticals (CNSP) Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Mar 9, 2023 09:05AM CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
View Older Stories